
|Articles|September 1, 2016
- Pharmaceutical Executive-09-01-2016
- Volume 36
- Issue 9
Pharmaceutical Executive, September 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 9 years ago
Pharm Exec's Emerging Pharma Leaders 2016over 9 years ago
Emerging Leaders 2016: Lessons from the Front Benchover 9 years ago
Patient-Centered Strategies for Clinical Trials & Treatmentover 9 years ago
Rise of the Vox Populiover 9 years ago
Opioid Epidemic Prompts More Finger Pointing at Pharmaover 9 years ago
Country Report: France, Part IINewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
2
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
3
JP Morgan 2026 Preview: Roche’s Refresh
4
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
5




